Chemistry:Azagly-nafarelin
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Trade names | Gonazon |
| Other names | 6-[3-(2-Naphthalenyl)-D-alanine]-1-9-luteinizing hormone-releasing factor (swine) 2-(aminocarbonyl)hydrazide; 6-[3-(2-Naphthalenyl)-D-alanine]-10-deglycinamide-luteinizing hormone-releasing factor (pig) 2-(aminocarbonyl)hydrazide |
| Routes of administration | Implant; Injection |
| Drug class | GnRH agonist |
| Identifiers | |
| |
| CAS Number |
|
| UNII | |
| Chemical and physical data | |
| Formula | C65H82N18O13 |
| Molar mass | 1323.484 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Azagly-nafarelin, sold under the brand name Gonazon, is a gonadotropin-releasing hormone agonist (GnRH agonist) medication which is used in veterinary medicine in Europe.[1][2] It is a GnRH analogue and a synthetic peptide, specifically a decapeptide.[1][2][3] The medication has been approved in Europe as a solid silicone-based matrix implant for use as a contraceptive in animals such as male dogs, cats, and others, but is no longer or was never commercially available.[1][2][4][5] The medication has also been used to treat benign prostatic hyperplasia in animals.[6][7] In addition to its use in mammals, azagly-nafarelin has been approved for use in aquaculture fish, specifically to control ovulation in salmonids, and was the first GnRH agonist to be available for use in fish.[2][8] It was introduced for use by 2005.[9]
See also
References
- ↑ 1.0 1.1 1.2 "Male Contraception in Animal Species". Encyclopedia of Reproduction. Elsevier Science. 29 June 2018. pp. 554–556. ISBN 978-0-12-815145-7. https://books.google.com/books?id=m4RlDwAAQBAJ&pg=PA554.
- ↑ 2.0 2.1 2.2 2.3 Pharmakotherapie bei Haus- und Nutztieren: Begründet von W. Löscher, F.R. Ungemach und R. Kroker. Enke. 3 September 2014. pp. 435–. ISBN 978-3-8304-1251-9. https://books.google.com/books?id=g1ldBAAAQBAJ&pg=PA435.
- ↑ "Signaling events associated with gonadotropin releasing hormone-agonist-induced hormonal castration and its reversal in canines". Molecular Reproduction and Development 83 (12): 1092–1101. December 2016. doi:10.1002/mrd.22751. PMID 27764533.
- ↑ "New approaches to non-surgical sterilization for dogs and cats: Opportunities and challenges". Reproduction in Domestic Animals = Zuchthygiene 52 (Suppl 2): 327–331. April 2017. doi:10.1111/rda.12862. PMID 27892642.
- ↑ "Male Animal Contraception". Animal Andrology: Theories and Applications. CABI. 30 April 2014. pp. 489–. ISBN 978-1-78064-316-8. https://books.google.com/books?id=hv6dAwAAQBAJ&pg=PA489.
- ↑ "Canine Prostate Disease". Veterinary Clinics of North America: Small Animal Practice (Elsevier Health Sciences) 48 (4): 701–719. July 2018. doi:10.1016/j.cvsm.2018.02.012. ISBN 978-0-323-61085-8. PMID 29933768. https://books.google.com/books?id=zLJhDwAAQBAJ&pg=PA707.
- ↑ "Hormonbehandlung bei der Hüdin". Klinik der Reproduktionsmedizin des Hundes. Schlütersche Verlagsgesellschaft mbH & Company KG. 6 December 2010. pp. 286–. ISBN 978-3-8426-8038-8. https://books.google.com/books?id=550uBQAAQBAJ&pg=PA286.
- ↑ "Promoting oocyte maturation, ovulation, and spawning in farmed fish". The Fish Oocyte: From Basic Studies to Biotechnological Applications. Springer Science & Business Media. 20 August 2007. pp. 444–. ISBN 978-1-4020-6233-9. https://books.google.com/books?id=7ViiIK-lK2sC&pg=PA444.
- ↑ "Optimization of breeding of salmonids: Gonazon, the first officially approved inducer of ovulation in the EU". World Aquaculture. 2005. http://agris.fao.org/agris-search/search.do?recordID=US201300988052. Retrieved 2018-07-29.
 |  |
